Literature DB >> 22981459

Human plasma-derived BuChE as a stoichiometric bioscavenger for treatment of nerve agent poisoning.

Helen Mumford1, Cerys J Docx, Matthew E Price, A Christopher Green, John E H Tattersall, Stuart J Armstrong.   

Abstract

Potent organophosphorous (OP) agents, such as VX, are hazardous by absorption through the skin and are resistant to conventional pharmacological antidotal treatments. The residence time of a stoichiometric bioscavenger, human butyrylcholinesterase (huBuChE), in the plasma more closely matches that of VX than do the residence times of conventional therapy drugs (oxime, anti-muscarinic, anticonvulsant). Intramuscular (i.m.) huBuChE afforded almost complete protection when administered prior to the onset of observable cholinergic signs of VX poisoning, but once signs of poisoning became evident the efficacy of i.m. huBuChE decreased. A combination of nerve agent therapy drugs (oxime, anti-muscarinic, anticonvulsant) with huBuChE (i.m.) protected 100% (8/8) of guinea-pigs from a lethal dose of VX (0.74 mg/kg) to 48 h, even when administered on signs of poisoning. Survival was presumed to be due to immediate alleviation of the cholinergic crisis by the conventional pharmacological treatment drugs, in conjunction with bioscavenger that prevented further absorbed agent reaching the AChE targets. Evidence to support this proposed mechanism of action was obtained from PKPD experiments in which multiple blood samples and microdialysate samples were collected from individual conscious ambulatory animals. Plasma concentrations of intramuscularly-administered atropine, diazepam and HI-6 reached a peak within 15 min and were eliminated rapidly within 4h. Plasma concentrations of huBuChE administered by the i.m. route took approximately 24h to reach a peak, but were well-maintained over the subsequent 7days. Thus, the pharmacological therapy rapidly treated the initial signs of poisoning, whilst the bioscavenger provided prolonged protection by neutralising further nerve agent entering the bloodstream and preventing it from reaching the target organs. Crown
Copyright © 2012. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22981459     DOI: 10.1016/j.cbi.2012.08.018

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  10 in total

1.  Selection of a human butyrylcholinesterase-like antibody single-chain variable fragment resistant to AChE inhibitors from a phage library expressed in E. coli.

Authors:  Adriano Podestà; Serena Rossi; Ilaria Massarelli; Sara Carpi; Barbara Adinolfi; Stefano Fogli; Anna Maria Bianucci; Paola Nieri
Journal:  MAbs       Date:  2014 Jul-Aug       Impact factor: 5.857

Review 2.  Organophosphate-Hydrolyzing Enzymes as First-Line of Defence Against Nerve Agent-Poisoning: Perspectives and the Road Ahead.

Authors:  A R Satvik Iyengar; Abhay H Pande
Journal:  Protein J       Date:  2016-12       Impact factor: 2.371

3.  New therapeutic approaches and novel alternatives for organophosphate toxicity.

Authors:  Francine S Katz; Stevan Pecic; Laura Schneider; Zhengxiang Zhu; Ashley Hastings; Michal Luzac; Joanne Macdonald; Donald W Landry; Milan N Stojanovic
Journal:  Toxicol Lett       Date:  2018-03-31       Impact factor: 4.372

4.  Optimization of Cholinesterase-Based Catalytic Bioscavengers Against Organophosphorus Agents.

Authors:  Sofya V Lushchekina; Lawrence M Schopfer; Bella L Grigorenko; Alexander V Nemukhin; Sergei D Varfolomeev; Oksana Lockridge; Patrick Masson
Journal:  Front Pharmacol       Date:  2018-03-13       Impact factor: 5.810

5.  Three-dimensional brain-on-chip model using human iPSC-derived GABAergic neurons and astrocytes: Butyrylcholinesterase post-treatment for acute malathion exposure.

Authors:  Lumei Liu; Youngmi Koo; Teal Russell; Elaine Gay; Yan Li; Yeoheung Yun
Journal:  PLoS One       Date:  2020-03-12       Impact factor: 3.240

6.  The potential of microdialysis to estimate rifampicin concentrations in the lung of guinea pigs.

Authors:  Faye Lanni; Neil Burton; Debbie Harris; Susan Fotheringham; Simon Clark; Oliver Skinner; Nathan Wiblin; Mike Dennis; Stuart Armstrong; Geraint Davies; Ann Williams
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

7.  Could Small Neurotoxins-Peptides be Expressed during SARS-CoV-2 Infection?

Authors:  Concetta Cafiero; Alessandra Micera; Agnese Re; Loredana Postiglione; Andrea Cacciamani; Beniamino Schiavone; Giulio Benincasa; Raffaele Palmirotta
Journal:  Curr Genomics       Date:  2021-12-31       Impact factor: 2.236

8.  Expression of human butyrylcholinesterase with an engineered glycosylation profile resembling the plasma-derived orthologue.

Authors:  Jeannine D Schneider; Alexandra Castilho; Laura Neumann; Friedrich Altmann; Andreas Loos; Latha Kannan; Tsafrir S Mor; Herta Steinkellner
Journal:  Biotechnol J       Date:  2013-11-08       Impact factor: 4.677

9.  Toxicity and medical countermeasure studies on the organophosphorus nerve agents VM and VX.

Authors:  Helen Rice; Christopher H Dalton; Matthew E Price; Stuart J Graham; A Christopher Green; John Jenner; Helen J Groombridge; Christopher M Timperley
Journal:  Proc Math Phys Eng Sci       Date:  2015-04-08       Impact factor: 2.704

Review 10.  Acetylcholinesterase: The "Hub" for Neurodegenerative Diseases and Chemical Weapons Convention.

Authors:  Samir F de A Cavalcante; Alessandro B C Simas; Marcos C Barcellos; Victor G M de Oliveira; Roberto B Sousa; Paulo A de M Cabral; Kamil Kuča; Tanos C C França
Journal:  Biomolecules       Date:  2020-03-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.